These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12197218)

  • 1. Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer.
    Kuzel TM; Kies MS; Wu N; Hsieh YC; Rademaker AW
    Cancer Invest; 2002; 20(5-6):634-43. PubMed ID: 12197218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
    Haas N; Roth B; Garay C; Yeslow G; Entmacher M; Weinstein A; Rogatko A; Babb J; Minnitti C; Flinker D; Gillon T; Hudes G
    Urology; 2001 Jul; 58(1):59-64. PubMed ID: 11445480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.
    Vaishampayan U; Fontana J; Du W; Hussain M
    Urology; 2002 Dec; 60(6):1050-4. PubMed ID: 12475668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
    Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer.
    Segawa T; Kamoto T; Kinoshita H; Kunishima Y; Yoshimura K; Ito A; Takahashi T; Higashi S; Nakamura E; Nishiyama H; Ito N; Yamamoto S; Habuchi T; Ogawa O
    Int J Clin Oncol; 2005 Oct; 10(5):333-7. PubMed ID: 16247660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
    J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study.
    Kuruma H; Fujita T; Shitara T; Egawa S; Yokoyama E; Baba S
    Int J Urol; 2003 Sep; 10(9):470-5. PubMed ID: 12941125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.
    Berry WR; Hathorn JW; Dakhil SR; Loesch DM; Jackson DV; Gregurich MA; Newcomb-Fernandez JK; Asmar L
    Clin Prostate Cancer; 2004 Sep; 3(2):104-11. PubMed ID: 15479494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ
    J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
    Mathew P; Logothetis CJ; Dieringer PY; Chen I; Pagliaro LC; Bekele BN; Zhou X; Daliani DD
    Clin Genitourin Cancer; 2006 Sep; 5(2):144-9. PubMed ID: 17026803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
    Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
    Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
    Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
    Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
    Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
    Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
    Petrylak DP; Macarthur RB; O'Connor J; Shelton G; Judge T; Balog J; Pfaff C; Bagiella E; Heitjan D; Fine R; Zuech N; Sawczuk I; Benson M; Olsson CA
    J Clin Oncol; 1999 Mar; 17(3):958-67. PubMed ID: 10071290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.